Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06686602 · ClinicalTrials.gov registry record

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

A clinical trial of Advanced/Metastatic NSCLC and Advanced/Metastatic HER2-negative Breast Cancer, sponsored by Daiichi Sankyo.

Completed
Registry status
13,759
Enrollment target
1
Study location

NCT06686602 is a study of Advanced/Metastatic NSCLC and Advanced/Metastatic HER2-negative Breast Cancer that has completed, run by Daiichi Sankyo. The registered enrollment target is 13,759 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06686602, a study of Advanced/Metastatic NSCLC and Advanced/Metastatic HER2-negative Breast Cancer, has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
13,759 participants
Enrollment target
1
Study location

Study Summary

This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

Interventions

  • OTHER No drug

Study Locations (1)

Massachusetts

  • ConcertAI Database - Cambridge

Trial Details

FieldValue
Enrollment Target 13,759 participants
Start Date 2024-07-09
Est. Completion 2025-03-18

Sponsor

Daiichi Sankyo

236 total trials

What the Registry Record Tells You About NCT06686602

The ClinicalTrials.gov registry entry for NCT06686602 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13,759 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced/Metastatic NSCLC appearing as the primary indexed condition, and to 1 intervention - of which No drug is the first listed.

NCT06686602 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06686602 about?

NCT06686602 is a clinical study titled "A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer". This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

What is the current status of trial NCT06686602?

This trial is currently completed. The enrollment target is 13,759 participants. The study started on 2024-07-09. Estimated completion is 2025-03-18.

What conditions does trial NCT06686602 study?

This clinical trial studies the following conditions: Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer.

What interventions are being tested in trial NCT06686602?

The interventions under investigation include: No drug (OTHER).

Who is sponsoring clinical trial NCT06686602?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06686602 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced/Metastatic NSCLC

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.